BioNexus Gene Lab Corp has 1 Schedule 13D or 13G filing on record since 2026-08-14. 1 holder's latest filing reports 5% or more of common stock, no par value. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Tan Lee Su-Leng | 11.5% | 338,709 | SCHEDULE 13D, 2026-08-14 | 2026-08-13 |
Purpose of Transaction (Item 4)
Tan Lee Su-Leng
The Reporting Person acquired the shares as compensation for completed services to the Issuer and in connection with the Reporting Person's service as Chief Executive Officer and President and as a director. The shares were not acquired with borrowed funds or for the purpose of acquiring control of the Issuer. By reason of the Reporting Person's executive and Board positions, the Reporting Person participates in the management, business, policies and strategic direction of the Issuer and may from time to time consider, discuss or support actions concerning the Issuer's business, operations, governance, capital structure, securities, financing, acquisitions or dispositions, Board composition, executive leadership and other matters that may fall within one or more of the categories described in Item 4(a) through (j) of Schedule 13D. Any such action would remain subject to the Reporting Person's fiduciary duties, applicable law, the Issuer's governing documents and required approvals. Except as described in this statement and in the Reporting Person's ordinary exercise of responsibilities as an executive officer and director, the Reporting Person has no present plan or proposal that relates to or would result in any action specified in Item 4(a) through (j) of Schedule 13D. The Reporting Person may review the investment on a continuing basis and may change this intention in light of future developments.Item 4 of the SCHEDULE 13D filed 2026-08-14
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-08-14 | Tan Lee Su-Leng | 11.5% | SCHEDULE 13D |
Tools for this story
Each opens in a new tab, filled in for BioNexus Gene Lab Corp. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.